Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elinzanetant for vasomotor symptoms of menopause
NCT03596762Phase 2Completed
- Sponsor
- Bayer
- Start
- Nov 2018
- Primary completion
- Nov 2019
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of elinzanetant in vasomotor symptoms of menopause (VMS), hot flashes and Insomnia (5 arms), sponsored by Bayer. Primary endpoint: Mean Change From Baseline in Mean Daily Frequency of Moderate and Severe Hot Flushes at 12 weeks. Started Nov 2018; status: completed.
02
Drugs
elinzanetant
03
Conditions
vasomotor symptoms of menopause (VMS)hot flashesInsomnia
Beyond the preview
Go deeper on NCT03596762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03596762.